Hallucinogenic Drug Helps Patients with Advanced Cancer
NYU Langone study finds the hallucinogenic drug psilocybin, when combined with counseling, relieves depression and anxiety in cancer patients.
Post-Traumatic Stress Disorder Treatment with Psychedelic Drugs | NYU Langone Health
NYU Langone’s High School Bioethics Project examines PTSD and the ethical implications of using psychedelics like psilocybin to treat symptoms. Learn More
Psychedelic Drug Benefits Persist in People with Cancer
NYU Langone study finds a psychedelic drug improved emotional distress in people with cancer for nearly five years after treatment.
Novel Therapeutic Agents for Hard-to-Treat Mental Conditions
NYU Langone’s Dr. Michael P. Bogenschutz, Dr. Stephen Ross, and colleagues explore therapeutic agents such as psilocybin, cannabidiol, and MDMA.
Podcast: Rethinking the Role of Psychedelics in Medicine
NYU Langone psychiatrist Dr. Stephen Ross sees potential for psychedelic drugs to treat anxiety, depression, and other mental health disorders.
Podcast: How the Pandemic Has Changed These Doctors
Three NYU Langone doctors discuss the impact of the COVID-19 pandemic on healthcare and new advances in their fields.
High School Bioethics Project Learning Scenarios | NYU Langone Health
Teachers may use our learning scenarios, or short bioethics primers, to supplement their curricula. Learn More
Substance Use Disorder Research | NYU Langone Health
NYU Langone’s Department of Psychiatry conducts research to further understand substance use disorder causes and treatments. Learn More
NYU Langone Establishes New Center for Psychedelic Medicine
NYU Langone Health opens a comprehensive Center for Psychedelic Medicine, building on its leadership position in this resurging field.
Psychedelic Medicine Research Training Program | NYU Langone Health
Physician–scientists in NYU Langone’s Department of Psychiatry offer a postdoctoral psychedelic medicine research training program. Learn More
